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Abstract: (250 words; limit 250) 
Background & Aims: The efficacy and tolerability of faldaprevir, a potent hepatitis C 
virus (HCV) NS3/4A protease inhibitor, plus peginterferon and ribavirin was 
assessed in a double-blind, placebo-controlled phase 3 study of treatment-naïve 
patients with HCV genotype-1 infection. 
Methods: Patients were randomly assigned (1:2:2) to peginterferon/ribavirin plus: 
placebo (arm 1, n=132) for 24 weeks; faldaprevir (120 mg, once daily) for 12 or 24 
weeks (arm 2, n=259); or faldaprevir (240 mg, once daily) for 12 weeks (arm 3, 
n=261). In arms 2 and 3, patients with early treatment success (HCV RNA <25 
IU/mL at week 4 and undetectable at week 8) stopped all treatment at week 24. 
Other patients received peginterferon/ribavirin until week 48 unless they met futility 
criteria. The primary endpoint was sustained virologic response 12 weeks post-
treatment (SVR12). 
Results: SVR12 was achieved by 52%, 79%, and 80% of patients in arms 1, 2, and 
3, respectively (estimated difference for arms 2 and 3 versus arm 1: 27%, 95% 
confidence interval 17%–36%; and 29%, 95% confidence interval, 19%–38%, 
respectively; P<.0001 for both). Early treatment success was achieved by 87% (arm 
2) and 89% (arm 3) of patients, of whom 86% and 89% achieved SVR12. Adverse 
event rates were similar among groups; few adverse events led to discontinuation of 
all regimen components. 
Conclusions: Faldaprevir plus peginterferon/ribavirin significantly increased SVR12, 
compared with peginterferon/ribavirin, in treatment-naïve patients with HCV 
genotype-1 infection. There do not seem to be any differences in responses of 
patients given once-daily 120 or 240 mg faldaprevir.  
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ClinicalTrials.gov: NCT01343888. 
Keywords: NS3/4A protease inhibitor; SVR12; early treatment success; DAA; 
clinical trial; phase 3  
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Introduction 
The introduction of the hepatitis C virus (HCV) NS3/4A protease inhibitors (PI) 
telaprevir and boceprevir represented a major advance in the treatment of chronic 
HCV genotype-1. Telaprevir or boceprevir with peginterferon and ribavirin resulted in 
a sustained virologic response (SVR) in 63%–75% of treatment-naïve patients, 
compared with 38%–44% with peginterferon and ribavirin alone [1–4]. However, 
these drugs have limitations, including serious skin reactions with telaprevir [5], and 
an increased incidence of anemia, compared with peginterferon and ribavirin alone, 
with both telaprevir and boceprevir [1–4]. Furthermore, both drugs also display a 
wide range of drug–drug interactions (DDIs), have a high pill burden, and require 
twice-daily (BID) or three-times-daily dosing [5–9]. 
Faldaprevir (BI 201335) is a potent HCV NS3/4A PI administered once daily [10–12]. 
Four phase 2 studies evaluated the efficacy and safety of faldaprevir with 
peginterferon alfa-2a plus ribavirin [13–16]. In genotype-1 treatment-naïve patients, 
SVR rates of up to 84% were achieved compared with 56% for placebo plus 
peginterferon and ribavirin [13]. In addition, SVR rates were similar with faldaprevir 
120 mg for 12 or 24 weeks [16]. The addition of faldaprevir to peginterferon and 
ribavirin was not associated with an increased incidence of anemia compared with 
peginterferon and ribavirin alone [13,16] and there have been no reports of 
potentially life-threatening cutaneous adverse reactions in phase 2 studies 
[13,14,16]. Studies of faldaprevir and antiretrovirals have shown a lower potential for 
DDIs than first-wave PIs [17]. 
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STARTVerso1 was a phase 3 study designed to assess the efficacy and safety of 
faldaprevir with peginterferon and ribavirin in treatment-naïve patients with chronic 
HCV genotype-1 infection. 
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Patients and methods 
Patients 
Patients were recruited from nine European countries and Japan. Eligible patients 
were treatment-naïve, aged 18–70 years (Europe), or 20–70 years (Japan), with 
chronic HCV genotype-1 infection diagnosed by positive anti-HCV antibodies and 
HCV RNA ≥1000 IU/mL at screening plus a positive antibody or HCV RNA test more 
than 6 months before screening, or a liver biopsy consistent with chronic HCV 
infection.  
Patients with compensated liver disease, including cirrhosis, were eligible for 
inclusion. All patients had a liver biopsy within 3 years or a fibroscan within 6 months 
of randomization to determine fibrosis stage. For patients without a liver biopsy, 
fibrosis stage was determined by fibroscan results using a cut-off value of 9.5 kPa to 
indicate fibrosis stage ≥F3 (<9.5 kPa F0–F2; ≥9.5 kPa F3–F4), consistent with 
evaluations of the use of fibroscan in chronic HCV [18,19]; however, there are no 
reliable cut-offs in the literature for distinguishing <F3 from ≥F3. The fibroscan 
threshold for cirrhosis was ≥13 kPa, based on the results of a meta-analysis by 
Friedrich-Rust et al, and consistent with results of other studies [20,21]. Main 
exclusion criteria included mixed-genotype HCV; HIV or hepatitis B co-infection; 
decompensated liver disease; and contraindications to peginterferon or ribavirin. 
Asian patients were limited to 20% of the total population. 
Study design 
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group 
phase 3 study (Figure 1). Patients were randomized 1:2:2 to arm 1, 2, or 3. Patients 
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in arm 1 received placebo plus peginterferon and ribavirin for 24 weeks, then 
peginterferon and ribavirin for 24 weeks. Patients in arm 2 received faldaprevir 
120 mg once daily plus peginterferon and ribavirin. Those with early treatment 
success (ETS, HCV RNA <25 IU/mL target detected [TD] or target not detected 
[TND] at week 4 and <25 IU/mL TND at week 8) stopped faldaprevir at week 12 and 
received placebo plus peginterferon and ribavirin for a further 12 weeks. Patients 
without ETS received faldaprevir plus peginterferon and ribavirin for 24 weeks, then 
peginterferon and ribavirin for a further 24 weeks. In arm 3, all patients received 
faldaprevir 240 mg once daily plus peginterferon and ribavirin for 12 weeks followed 
by placebo plus peginterferon and ribavirin to week 24, and either stopped treatment 
(ETS) or continued peginterferon and ribavirin to week 48 (no ETS) (Figure 1). A 
single loading dose of faldaprevir was administered on Day 1 (arm 2=240 mg; arm 
3=480 mg). All study medication was stopped in the event of virologic breakthrough 
at or after week 4 (increase in HCV RNA ≥1 log10 from nadir or ≥25 IU/mL after an 
initial decrease to <25 IU/mL), lack of early virologic response (EVR; decrease in 
HCV RNA ≥2 log10 from baseline at week 12), or lack of virologic response 
(detectable HCV RNA at week 24).  
Peginterferon (alfa-2a) was administered subcutaneously at 180 µg once weekly. 
Ribavirin was administered orally at a total dose of 1000 or 1200 mg (for bodyweight 
<75 kg or ≥75 kg, respectively) daily in two divided doses, except in Japan where the 
total dose was 600, 800, or 1200 mg (for bodyweight ≤60 kg, >60–≤80 kg, or >80 kg, 
respectively) daily in two divided doses according to the local label. Both faldaprevir 
and ribavirin were given with food, a requirement of ribavirin but not faldaprevir 
administration. Dose reductions were permitted for peginterferon and ribavirin, and 
brief dose interruptions were permitted for all three drugs, but only if medically 
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necessary and following discussion with the clinical monitor. Faldaprevir 
monotherapy was not permitted. Treatment compliance was monitored using pill 
counts and syringe counts at each visit.  
Concomitant use of the following drugs was not permitted: immunomodulators 
(including chronic use of systemic corticosteroids); systemic antiviral agents (except 
for treatment of mild, localized, recurrent herpes simplex, or influenza); and 
medications that could cause phototoxicity (except ribavirin). Concomitant treatment 
with methadone or buprenorphine was excluded, and the use of substrates of P-
glycoprotein, UGT1A1, CYP3A4, or CYP2C9 with a narrow therapeutic window was 
discouraged.  
Study documentation, including protocol amendments, was approved by the 
appropriate institutional review board and the study was carried out in accordance 
with the Declaration of Helsinki and International Conference on Harmonisation 
guidelines. All patients provided written informed consent. An independent data 
monitoring committee reviewed the efficacy and safety data at regular intervals. All 
authors had access to the study data and reviewed and approved the final 
manuscript. 
Randomization and blinding 
Randomization was carried out using an interactive voice response system, and was 
stratified according to race (Black, Asian, other) and HCV genotype (genotype-1a, 
genotype-1b, other). Investigators, sponsor, and patients were blinded to treatment 
group allocation through the use of matching placebo capsules. HCV RNA results 
were blinded up to week 8. 
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Virologic endpoints 
The primary endpoint was SVR (HCV RNA <25 IU/mL TND) 12 weeks after 
completion of therapy (SVR12). Secondary endpoints were ETS, and ALT and AST 
normalization. Other endpoints were rapid virologic response (RVR, HCV RNA <25 
IU/mL TD or TND at week 4); complete EVR (cEVR, HCV RNA <25 IU/mL TND at 
week 12); and end of treatment response (ETR, HCV RNA <25 IU/mL TND at end of 
treatment).  
HCV RNA levels were measured using the quantitative Roche COBAS® Taqman 
HCV/HPS assay version 2 (lower limit of quantification 25 IU/mL; limit of detection 9–
20 IU/mL).The primary endpoint was changed from SVR24 to SVR12 by a protocol 
amendment, consistent with evidence of concordance between SVR12 and SVR24 
[22]. 
Resistance monitoring 
Samples were obtained for viral sequencing at baseline and at study visits. Baseline 
samples and samples from patients who did not achieve SVR12 were analyzed. 
HCV RNA was amplified by reverse transcriptase polymerase chain reaction and 
population sequencing performed on the NS3 or NS3/4A regions (Big Dye 
Terminator and an ABI 3730XL Genetic Analyser [Applied Biosystems]). 
Safety assessments 
Safety was assessed by monitoring adverse events (AEs) and laboratory parameters 
throughout the trial and 28 days post-treatment. Patients with persisting AEs were 
monitored until the event resolved. With the exception of photosensitivity, AEs were 
graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or potentially life-
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threatening (Grade 4) using the Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events (DAIDS) [23]. Photosensitivity was graded as 
mild, moderate, or severe according to predefined criteria (see Supplementary 
tables). A rash management plan was used to reduce the progression of rash 
intensity and minimize the risk of photosensitivity. Patients were provided with sun 
protection and were instructed to protect eyes and skin from sun- or UV-light 
exposure using protection with a sun protection factor ≥30 providing UVA and UVB 
coverage.  
 
Statistical analysis 
Based on a sample size of 125 patients in the placebo arm and 250 patients in each 
of the faldaprevir arms, the study was anticipated to have a power of 96% to detect, 
with alpha = 0.05 (2-sided), an effect size of 20% for the primary endpoint, assuming 
an SVR12 of 50% in the placebo arm. 
The primary efficacy analyses were based on the intention-to-treat (ITT) population 
(all randomized patients who received at least one dose of study medication). The 
safety analysis set included all patients who received at least one dose of study 
medication regardless of randomization. 
The proportion of patients with SVR12 was compared pairwise using the Cochran–
Mantel–Haenszel test, stratified by race and genotype-1 subtype. A hierarchical 
testing strategy was pre-specified, with the test for the lower dose only interpreted if 
the higher dose was statistically significant. Thus, no alpha adjustment was 
necessary. ETS was summarized descriptively (numbers and proportions of patients 
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reaching the endpoint in each arm). All other efficacy and safety data were 
summarized descriptively. 
Positive and negative predictive values (PPVs and NPVs) for SVR12 based on 
different HCV RNA thresholds (1000 IU/mL, 100 IU/mL, 25 IU/mL, and detectable) 
were calculated for all faldaprevir-treated patients with HCV RNA measurements at 
weeks 2, 4, 8, and 12 on treatment.  
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Results 
Patients 
Patients were enrolled from April 14 through November 11, 2011 at 102 sites from 
10 European countries and Japan; the last patient completed follow-up on February 
12, 2013. All patients were enrolled prior to the availability of telaprevir or boceprevir 
in Europe and Japan. Of 778 patients screened, 656 were randomized and 652 were 
treated with placebo (n=132), faldaprevir 120 mg (n=259), or faldaprevir 240 mg 
(n=261) (Figure 2). The baseline demographic characteristics were similar across the 
arms (Table 1). Liver biopsies were available for 312/652 patients—115 (44%), 131 
(51%), and 66 (50%) in the faldaprevir 120 mg, faldaprevir 240 mg, and placebo 
arms, respectively. Fibroscan scores were available for 353/652 patients—148 
(57%), 138 (53%), and 67 (51%) in the faldaprevir 120 mg, faldaprevir 240 mg, and 
placebo arms, respectively.  
Efficacy 
SVR12 rates were significantly higher for faldaprevir 120 mg or 240 mg compared 
with placebo (79% and 80% compared with 52%, respectively; Table 2a). The 
estimated differences in SVR12 of faldaprevir vs placebo were 27% (95% CI: 17–36) 
for faldaprevir 120 mg (P<.0001) and 29% (95% CI: 19–38) for faldaprevir 240 mg 
(P<.0001). The higher SVR12 rates with faldaprevir compared with placebo were 
also observed in subgroup analyses. SVR12 rates were similar for both doses of 
faldaprevir among all subgroups analyzed (Table 2b, Supplementary Figure 1). 
However, the number of patients in the cirrhotic subgroup was small.  
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Overall, 87% and 89% of patients in the faldaprevir 120 mg and 240 mg arms, 
respectively, achieved ETS (Table 2a). Of those, 86% (faldaprevir 120 mg) and 89% 
(faldaprevir 240 mg) achieved SVR12. In both faldaprevir arms, among patients with 
ETS who completed 24 weeks of therapy, those with undetectable HCV RNA at 
week 4 had numerically higher rates of SVR12 than those with HCV RNA <25 IU/mL 
detectable at week 4 (faldaprevir 120 mg: 91% [155/171] vs 77% [30/39]; faldaprevir 
240 mg: 94% [167/178] vs 72% [21/29]).  
RVR was achieved by 91% and 93% of patients in the faldaprevir 120 mg and 240 
mg arms, respectively, versus 22% in the placebo group (Table 2a). cEVR was 
achieved by 90% of patients in both faldaprevir goups, versus 46% in the placebo 
group. Among faldaprevir-treated patients with RVR, 83% (faldaprevir 120 mg) and 
86% (faldaprevir 240 mg) achieved SVR12. Among those with cEVR, 85% 
(faldaprevir 120 mg) and 88% (faldaprevir 240 mg) achieved SVR12.  
Based on pooled data from both faldaprevir arms, week 4 HCV RNA <25 IU/mL 
resulted in a PPV (for SVR12) of 85%; week 4 HCV RNA undetectable resulted in a 
PPV of 90% (Supplementary Table 1). The NPV of week 4 HCV RNA ≥25 IU/mL was 
87%, and of week 4 HCV RNA ≥100 IU/mL was 100%. Using a threshold of week 4 
HCV RNA detectable (either TD or HCV-RNA quantifiable) resulted in an NPV of 
50%, while using a threshold of week 12 HCV RNA detectable (i.e., not achieving 
cEVR) resulted in an NPV of 95%.  
Breakthrough occurred in 42 patients across all treatment arms, 23 of whom were 
infected with HCV genotype-1a (Table 3). Relapse occurred in 21%, 11%, and 9% of 
patients in the placebo, faldaprevir 120 mg, and faldaprevir 240 mg arms, 
respectively, and was more common in patients infected with genotype-1a (Table 3). 
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One patient who received faldaprevir (0.2%) and 15 who received placebo (11%) 
had a null or partial response (Table 3). Of the 33 patients in the faldaprevir 120 mg 
arm without ETS who continued faldaprevir beyond week 12, 13 (39%) experienced 
viral breakthrough and 3 (9%) relapsed.  
Of the faldaprevir-treated patients who failed to achieve SVR12, 87% (92/106) had 
an emergent resistance-associated variant (RAV). The most common emergent 
RAVs were R155K (31/48, 65%) and substitutions at D168 (43/44, 98%) in patients 
infected with genotype-1a and genotype-1b, respectively. None of the clinically 
relevant NS3 polymorphisms [24] detected at baseline (Supplementary Table 2), 
including the Q80K polymorphism (detected in 49/217 [23%] of patients infected with 
genotype-1a) were associated with a reduction in SVR12. SVR12 was achieved by 
99/139 (71%) of faldaprevir-treated patients with wild-type Q80 versus 25/33 (76%) 
with the Q80K polymorphism (P=.67; Supplementary Table 3).  
Safety 
AEs led to discontinuation of all study medications in 4% (5/132), 4% (10/259), and 
5% (14/261) of patients treated with placebo, faldaprevir 120 mg, or faldaprevir 240 
mg, respectively (Table 4). Discontinuation of faldaprevir only occurred in 1% (2/259) 
of patients in the 120 mg arm and 3% (8/261) of patients in the 240 mg arm. The 
most common AEs leading to discontinuation of faldaprevir were vomiting, nausea, 
jaundice, and rash (Supplementary Table 4).  
Serious AEs were reported in 6%, 7%, and 7% of patients treated with placebo, 
faldaprevir 120 mg, or faldaprevir 240 mg, respectively. Mild AEs were reported by 
52%, 48%, and 45%, moderate AEs by 33%, 31%, and 37%, and severe AEs by 
14%, 19%, and 15% of patients treated with placebo, faldaprevir 120 mg, or 
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faldaprevir 240 mg, respectively. Gastrointestinal (GI) AEs of at least moderate 
intensity were more frequent in patients who received faldaprevir 240 mg vs 120 mg 
or placebo. The most frequently reported AEs of at least moderate intensity and 
serious AEs are summarized in Table 4. 
Severe rash occurred in <1% of patients in each of the faldaprevir arms; no patient 
had life-threatening rash (Supplementary Table 5). Discontinuations of only 
faldaprevir or placebo due to rash occurred in two patients. Photosensitivity was 
infrequent (n=15, 2%), with the majority of events occurring in the faldaprevir 240 mg 
arm (10/15). All but two events were classified as mild (Supplementary Table 5) and 
no discontinuations were reported due to photosensitivity. 
Grade 3–4 abnormalities in white blood cells, platelets, neutrophils, and lymphocytes 
occurred with similar frequency across the treatment arms (Supplementary Table 6). 
There was no difference in hemoglobin levels between the treatment arms at any 
visit (Figure 3). Up to week 24, proportions of patients with hemoglobin levels ≤10 
g/dL and ≤8.5 g/dL were similar across treatment arms (Supplementary Table 6). 
The numbers of patients with hemoglobin reductions leading to ribavirin dose 
reduction were 32 (24%), 44 (17%), and 39 (15%) in the placebo, faldaprevir 120 
mg, and 240 mg arms, respectively. Twenty-six patients received erythropoietin (4 
[3%], 10 [4%], and 12 [5%], respectively). Among all patients with ribavirin dose 
reductions, SVR12 was 67% (21/32), 86% (50/58), and 84% (37/44) in the placebo, 
faldaprevir 120 mg, and faldaprevir 240 mg arms, respectively. 
Total bilirubin levels more than 2.6 times the upper limit of normal (ULN) were more 
frequent in the faldaprevir arms. More patients had elevated bilirubin in the 
faldaprevir 240 mg arm than the 120 mg arm (Supplementary Table 6). Bilirubin 
elevations were characterized by predominantly unconjugated bilirubin, peaked 
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around week 4, and returned to baseline levels in all patients after the end of 
faldaprevir treatment (Supplementary Figure 2). Four patients in the faldaprevir 240 
mg arm had DAIDS Grade 3 or 4 total bilirubin and direct bilirubin:total bilirubin ratio 
>0.5. None of these patients had concurrent elevations in ALT or AST >3×ULN, or 
any clinical signs of liver injury.  
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Discussion 
This study demonstrated that once-daily faldaprevir combined with peginterferon and 
ribavirin was significantly more effective than peginterferon and ribavirin alone in 
treatment-naïve patients with HCV genotype-1 infection. The majority of patients 
(88%) were eligible to receive 12 weeks of faldaprevir plus peginterferon and 
ribavirin and stop all treatment at week 24; of these patients, 88% achieved SVR12. 
SVR12 rates were similar with the 120 mg and 240 mg doses of faldaprevir (79% 
and 80%, respectively), and significantly higher than with peginterferon and ribavirin 
alone (52%). An increase in SVR12 rates for faldaprevir over placebo was 
consistently observed across subgroups, although the study was not powered to 
assess statistical significance in the different subgroups and some subgroup 
comparisons are limited by small numbers. The increase in SVR12 for faldaprevir  
over placebo was higher in certain difficult-to-treat populations (HCV genotype-1a, 
high baseline HCV RNA, and IL28B non-CC) versus the easier-to-treat subgroup. 
Common baseline polymorphisms were not found to affect the efficacy of faldaprevir. 
The Q80K variant has been associated with reduced SVR12 in phase 3 studies of 
simeprevir [25,26]; however Q80K, present in 23% of genotype-1a-infected patients 
in this study, was not found to reduce SVR12 in faldaprevir-treated patients. As 
observed in phase 2 studies, RAVs encoding substitutions at positions R155 
(genotype-1a) or D168 (genotype-1b) of HCV NS3 emerged in the majority of 
patients who did not achieve SVR12 [13,14]. 
While differences in patient populations and trial designs preclude direct comparison 
of these data with other studies, the 27% increase in SVR12 with faldaprevir plus 
peginterferon and ribavirin compared with peginterferon and ribavirin alone was 
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similar to that reported in phase 3 trials of telaprevir (31% vs placebo), boceprevir 
(28% vs placebo), and simeprevir (30% vs placebo) plus peginterferon and ribavirin 
in treatment-naïve patients with HCV genotype-1 [2,3,25,27]. More patients were 
able to stop treatment at week 24 with faldaprevir compared with telaprevir and 
boceprevir (88% vs 58% and 47%, respectively), although that may be due in part to 
different HCV RNA criteria used for shortening treatment duration in the different 
trials [2,3]. Compared with simeprevir-treated patients, a similar proportion of 
faldaprevir-treated patients were able to stop at week 24 (88%) [25,27]. In all trials, 
patients who qualified for shortened treatment achieved a high SVR (>83%) 
[2,3,25,27]. 
Analysis of the predictive value of certain virologic endpoints suggests that a week 4 
stopping rule for faldaprevir plus peginterferon and ribavirin should not use a 
threshold of detectable HCV RNA: 50% of patients who met this criterion went on to 
achieve SVR12 with continued treatment. A week 4 stopping rule using a threshold 
of ≥25 IU/mL (NPV 87%) or ≥100 IU/mL (NPV 100%) would more reliably stop 
treatment in patients unlikely to achieve cure. 
The higher (240 mg QD) dose of faldaprevir was associated with a minor increase in 
AEs compared with the lower (120 mg QD) dose or compared with peginterferon and 
ribavirin alone. The rate of treatment discontinuation was similar between the 
faldaprevir 120 mg and placebo arms, and only slightly higher in the faldaprevir 240 
mg arm. The addition of faldaprevir increased the rate of rash observed with 
peginterferon and ribavirin alone. However, the incidence of rash was similar with 
both faldaprevir doses and was mainly mild in intensity. Photosensitivity reactions 
were rare, supporting the use of sun protection during treatment with faldaprevir. 
Grade 2–4 GI events were more common in the faldaprevir 240 mg arm, and 
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treatment discontinuation due to GI toxicities only occurred with this higher dose. 
These data indicate that faldaprevir may have a more favorable tolerability profile 
compared with telaprevir and boceprevir. While real-world data indicate that severe 
anemia is one of the most common AEs reported with first-wave PIs [28,29], 
faldaprevir did not increase the proportion of patients with hemoglobin levels below 
10 g/dL or 8.5 g/dL compared with placebo.  
As observed in phase 2 studies, faldaprevir was associated with a dose-dependent, 
transient, and benign elevation in predominantly unconjugated bilirubin [13,14]. 
Bilirubin levels returned to baseline after faldaprevir was stopped (Supplementary 
Figure 2). Faldaprevir inhibits the bilirubin conjugation enzyme, UGT1A1, and to a 
lesser extent the bilirubin transporters, OATP1B1, and MRP2 [30]. Increases in 
bilirubin have also been observed with simeprevir; however, this is predominantly 
driven by inhibition of OATP1B1 and MRP2 [31]. 
A possible limitation to this study is that investigators were unblinded to HCV RNA 
results after week 8, which could have effectively unblinded the treatment allocation. 
In addition, the effects of faldaprevir on bilirubin could have been used to infer 
treatment allocation. However, few patients withdrew consent in this study, so the 
effect is likely to be negligible. Another potential limitation is the lack of baseline 
histology data on many patients due to the widespread use of fibroscan in Europe. 
For patients without liver biopsies, we relied on fibroscan scores to stage fibrosis; 
although the fibroscan cut-off for cirrhosis is quite established, there is some 
disagreement about the optimal cut-off value for distinguishing <F3 from ≥F3 fibrosis 
[18–21]. Nevertheless, there is no gold standard for defining fibrosis stage at all, 
since sampling error is a major problem with inadequate sized liver biopsies [32]. 
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In addition to the results presented here, faldaprevir has shown efficacy as part of an 
interferon-based regimen for treatment-experienced patients (STARTVerso3) [33], 
and as part of an interferon-free regimen [34]. Regional differences in the cost of 
HCV therapies may lead to continued use of interferon-based regimens for the 
foreseeable future. Regimens that have been approved for treating genotype-1 
infection include sofosbuvir plus pegylated interferon and ribavirin [35] and 
simeprevir plus pegylated interferon and ribavirin [25,27]. For patients ineligible for 
interferon, sofosbuvir plus simeprevir with or without ribavirin is recommended [36].  
In conclusion, this phase 3 trial demonstrated that faldaprevir plus peginterferon and 
ribavirin significantly increased SVR12 in HCV genotype-1-infected treatment-naïve 
patients compared with peginterferon and ribavirin alone. While efficacy was similar 
for both doses of faldaprevir across all subgroups examined, the lower dose (120 
mg) was better tolerated, specifically regarding GI events and photosensitivity. Since 
the completion of this study, faldaprevir development has been terminated for non-
medical reasons in view of the fast progress in development of interferon-free 
regimens, and several all-oral direct-acting antiviral regimens have demonstrated 
high SVR12 rates with 12 weeks of treatment [37, 38]. The results of the current 
study mark an important milestone in HCV therapeutics, demonstrating the 
commitment of patients and investigators to HCV research and attesting to the rapid 
pace at which the field has evolved.  
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Tables 
Table 1. Baseline demographics and clinical characteristics 
 
Placebo + 
peginterferon and 
ribavirin 
(N=132) 
Faldaprevir 120 mg 
+ peginterferon 
and ribavirin 
(N=259) 
Faldaprevir 240 mg 
+ peginterferon 
and ribavirin 
(N=261) 
Male, n (%) 75 (57) 121 (47) 146 (56) 
Race, n (%)    
White 103 (78) 203 (78) 205 (79) 
Asian* 
Black/AA 
27 (20) 
2 (2) 
52 (20) 
3 (1) 
51 (20) 
4 (2) 
Other† 0 1 (<1) 1 (<1) 
Region, n (%)    
Europe 108 (82) 207 (80) 211 (81) 
Asia 24 (18) 52 (20) 50 (19) 
Mean age, years (SD) 46.6 (12.5) 47.9 (11.4) 48.3 (11.9) 
Mean BMI, kg/m2 (SD) 24.6 (4.3) 24.9 (4.2) 25.2 (4.6) 
HCV genotype-1 subtype, n 
(%)‡ 
   
1a 45 (34) 87 (34) 90 (34) 
1b 86 (65) 171 (66) 171 (66) 
Mean baseline HCV RNA, 
log10 IU/mL (SD) 
6.3 (0.7) 6.3 (0.7) 6.2 (0.8) 
Baseline HCV RNA  
≥800 000 IU/mL, n (%) 
101 (77) 201 (78) 185 (71) 
IL28B (rs12979860), n (%)     
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Placebo + 
peginterferon and 
ribavirin 
(N=132) 
Faldaprevir 120 mg 
+ peginterferon 
and ribavirin 
(N=259) 
Faldaprevir 240 mg 
+ peginterferon 
and ribavirin 
(N=261) 
CC 46 (35) 107 (41) 101 (39) 
CT 68 (52) 122 (47) 126 (48) 
TT 18 (14) 29 (11) 34 (13) 
Fibrosis stage, n (%)§    
<F3 107 (81) 212 (82) 219 (84) 
≥F3 
Missing 
25 (19) 
0 
45 (17) 
2 (1) 
42 (16) 
0 
Cirrhosisǁ, n (%) 8 (6) 16 (6) 15 (6) 
Mean ALT, IU/L (SD) 
[range] 
75 (68) 
[15–360] 
75 (69) 
[15–726] 
72 (52) 
[13–325] 
Elevated ALT, n (%) 84 (64) 169 (65) 177 (68) 
Elevated AST, n (%) 65 (49)** 117 (45) 133 (51) 
*Four Asian patients were enrolled outside Japan. †Includes American Indian/Alaskan Native, 
and Native Hawaiian/other Pacific Islander. ‡Two patients (one each in the placebo and 
faldaprevir 120 mg arms) were infected with HCV genotype-1, but subtyping was 
indeterminate. §Liver biopsies were available for 312/652 patients—115/259 (44%) in the 
faldaprevir 120 mg arm; 131/261 (51%) in the faldaprevir 240 mg arm; and 66/132 (50%) in 
the placebo arm. Fibroscan results were used to determine stage of fibrosis for patients 
without a liver biopsy (<F3 = <9.5 kPa, ≥F3 = ≥9.5 kPa) [18,19]. If a patient was indicated to 
have cirrhosis but had neither biopsy nor fibroscan data, they were classified as having ≥F3 
fibrosis. ǁCirrhosis was determined by the investigator based on fibroscan, biopsy, and/or 
other clinical parameters. **One patient had missing AST data at baseline. Reference 
ranges: ALT 0–35 U/L, AST 0–35 U/L.  
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AA, African American; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, 
body mass index; SD, standard deviation. 
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Table 2a. Virologic and biochemical responses (ITT) 
 
Placebo + 
peginterferon and 
ribavirin 
(N=132) 
Faldaprevir 120 
mg + 
peginterferon and 
ribavirin 
(N=259) 
Faldaprevir 240 mg 
+ peginterferon 
and ribavirin 
(N=261) 
SVR12, n (%) 69 (52) 204 (79) 210 (80) 
Estimate vs placebo, 
95% CI 
P 
– 26.7 
17.1, 36.3 
P<.0001 
28.6 
19.0, 38.2 
P<.0001 
ETS, n (%) 29 (22) 226 (87) 233 (89) 
RVR, n (%) 29 (22) 236 (91) 243 (93) 
cEVR, n (%) 60 (45) 233 (90) 236 (90) 
ETR, n (%) 97 (73) 238 (92) 240 (92) 
ALT normalization, n/N 
(%)* 
Baseline to EOT 
Baseline to SVR12 visit 
 
 
51/84 (61) 
40/84 (48) 
 
 
113/169 (67) 
132/169 (78) 
 
 
137/177 (77) 
132/177 (75) 
AST normalization, n/N 
(%)† 
Baseline to EOT 
Baseline to SVR12 visit 
 
 
38/65 (58) 
29/65 (45) 
 
 
88/117 (75) 
100/117 (85) 
 
 
92/133 (69) 
93/133 (70) 
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Table 2b. SVR12 by baseline subgroup (ITT) 
Subgroups 
 
 
n/N‡ (%) 
Placebo + peginterferon 
and ribavirin 
(N=132) 
Faldaprevir 120 mg 
+ peginterferon and 
ribavirin 
(N=259) 
Faldaprevir 240 mg 
+ peginterferon 
and ribavirin 
(N=261) 
Race    
White 
Asian 
Black 
49/103 (48) 
18/27 (67) 
2/2 (100)  
157/203 (77) 
44/52 (85) 
2/3 (67)  
158/205 (77) 
47/51 (92) 
4/4 (100) 
IL28B (rs12979860)    
CC 
CT 
TT 
29/46 (63) 
35/68 (51)  
5/18 (28) 
96/107 (90)  
85/122 (70) 
22/29 (76) 
96/101 (95) 
87/126 (69) 
27/34 (79) 
HCV genotype-1 
subtype 
   
1a 
1b 
16/45 (36) 
52/86 (60) 
60/87 (69) 
143/171 (84) 
68/90 (76) 
142/171 (83) 
Baseline HCV RNA    
<800 000 IU/mL 
≥800 000 IU/mL 
23/31 (74) 
46/101 (46) 
54/58 (93) 
150/201 (75) 
70/76 (92) 
140/185 (76) 
Cirrhosis    
Yes 
No 
3/8 (38) 
66/124 (53) 
9/16 (56) 
195/243 (80) 
6/15 (40) 
204/246 (83) 
Fibrosis stage    
≥F3 
<F3 
9/25 (36) 
60/107 (56) 
30/45 (67) 
172/212 (81) 
23/42 (55) 
187/219 (85) 
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*In patients with elevated baseline ALT. †In patients with elevated baseline AST; one patient  
not included due to missing baseline AST data. ‡Denominator is the total number of patients 
in each subgroup. ALT, alanine transaminase; AST, aspartate aminotransferase; cEVR, 
complete early virologic response (HCV RNA <25 IU/mL TND at week 12); EOT, end of 
treatment; ETR, end of treatment response (HCV RNA <25 IU/mL TND at end of all 
treatment); ETS, early treatment success (HCV RNA <25 IU/mL TD or TND at week 4 and 
<25 IU/mL, TND at week 8); RVR, rapid virologic response (HCV RNA <25 IU/mL TD or TND 
at week 4); SVR12, sustained virologic response (HCV RNA <25 IU/mL TND) 12 weeks post-
treatment. 
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Table 3. Patterns of treatment failure according to HCV genotype-1 subtype 
and treatment regimen 
 
Placebo + peginterferon 
and ribavirin 
Faldaprevir 120 mg + 
peginterferon and ribavirin 
Faldaprevir 240 mg + 
peginterferon and 
ribavirin 
 GT-1a 
(n=45) 
GT-1b 
(n=86) 
Total 
(n=132) 
GT-1a 
(n=87) 
GT-1b 
(n=171) 
Total 
(n=259) 
GT-1a 
(n=90) 
GT-1b 
(n=171) 
Total 
(n=261) 
Virologic 
breakthrough, n 
(%)* 
6 (13) 5 (6) 11 (8) 9 (10) 7 (4) 16 (6) 8 (9) 7 (4) 15 (6) 
0–12 weeks 1 (2) 1 (1) 2 (2) 5 (6) 2 (1) 7 (3) 3 (3) 3 (2) 6 (2) 
>12–24 weeks 3 (7) 1 (1) 4 (3) 2 (2) 4 (2) 6 (2) 3 (3) 3 (2) 6 (2) 
>24 weeks 2 (4) 3 (4) 5 (4) 2 (2) 1 (1) 3 (1) 2 (2) 1 (1) 3 (1) 
Null or partial 
response, n (%)† 
8 (18) 7 (8) 15 (11) 1 (1) 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 
Relapse‡, n/N 
(%) 
8/25  
(32) 
10/60  
(17) 
18/86§ 
(21) 
13/72 
(18) 
12/150  
(8) 
25/223§ 
(11) 
10/73  
(14) 
10/139  
(7) 
20/212  
(9) 
*Confirmed increase in HCV RNA ≥1 log10 from nadir or ≥25 IU/mL after an initial decrease 
to <25 IU/mL. †Null response, absence of HCV RNA drop by ≥2 log10 from baseline at week 
12; partial response, ≥2 log10 decrease in HCV RNA from baseline at week 12, but not 
achieving HCV RNA <25 IU/mL TND by end of treatment. ‡HCV RNA >25 IU/mL during 
follow-up (up to SVR12 visit) after decrease to <25 IU/mL TND at end of treatment. 
Denominator is number of patients who completed planned treatment and had ETR. §One 
patient in the placebo arm and one patient in the faldaprevir 120 mg arm had undetermined 
HCV genotype-1 subtype. Both achieved ETR and neither relapsed. 
ETR, end of treatment response; GT, genotype; TND, target not detected. 
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Table 4. Summary of adverse events (AEs)  
 Placebo + 
peginterferon 
and  
ribavirin 
(N=132) 
Faldaprevir 120 
mg + 
peginterferon 
and 
ribavirin 
(N=259) 
Faldaprevir 240 
mg + 
peginterferon 
and 
ribavirin 
(N=261) 
Any AE, n (%) 123 (93) 251 (97) 253 (97) 
AEs leading to discontinuation of 
faldaprevir or placebo, n (%) 
Of all study medications 
Of faldaprevir or placebo only 
 
5 (4) 
5 (4) 
0 (0) 
 
12 (5) 
10 (4) 
2 (1) 
 
22 (8) 
14 (5) 
8 (3) 
AEs of at least moderate 
intensity, n (%)* 
 
64 (48) 
 
134 (52) 
 
144 (55) 
Anemia† 
Neutropenia 
Rash‡ 
15 (11) 
15 (11) 
8 (6) 
33 (13) 
24 (9) 
21 (8) 
32 (12) 
17 (7) 
23 (9) 
Asthenia 4 (3) 15 (6) 13 (5) 
Fatigue 5 (4) 14 (5) 14 (5) 
Nausea 1 (1) 6 (2) 16 (6) 
Vomiting 
Bilirubin§ 
1 (1) 
2 (2) 
3 (1) 
8 (3) 
14 (5) 
16 (6) 
Any serious AE, n (%)ǁ 8 (6) 17 (7) 17 (7) 
Nervous system disorders 0 (0) 5 (2) 0 (0) 
Blood and lymphatic system 
disorders 
1 (1) 1 (<1) 4 (2) 
Gastrointestinal disorders 1 (1) 1 (<1) 3 (1) 
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 Placebo + 
peginterferon 
and  
ribavirin 
(N=132) 
Faldaprevir 120 
mg + 
peginterferon 
and 
ribavirin 
(N=259) 
Faldaprevir 240 
mg + 
peginterferon 
and 
ribavirin 
(N=261) 
Skin and subcutaneous tissue 
disorders 
1 (1) 1 (<1) 3 (1) 
General disorders and 
administration site conditions** 
 
1 (1) 
 
2 (1) 
 
1 (<1) 
Infections and infestations 1 (1) 1 (<1) 2 (1) 
*≥5% of patients in any treatment arm. Based on DAIDs grading system (Grade 
2=moderate; Grade 3=severe; Grade 4=life-threatening). †Includes all associated terms. 
‡Includes all associated terms (macropapular rash, macular rash, papular rash, 
erythematous rash, generalized rash, pruritic rash, drug eruption, toxic skin eruption, and 
urticaria). All patients with a moderate or severe rash or photosensitivity reaction were sent 
to a local expert dermatologist who reviewed the investigator’s assessment. Data from these 
patients were additionally sent to a rash adjudication committee to ensure consistency of 
grading/categorizing and reporting across regions and sites. §Bilirubin-associated events, 
including jaundice. ǁ≥3 patients across treatment arms. **Includes the following: in the 
placebo arm, adverse drug reaction (1); in the faldaprevir 120 mg arm, asthenia (1) and 
chest pain (1); and in the faldaprevir 240 mg arm, pyrexia (1).  
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Figure legends 
Fig. 1. STARTVerso1 study design 
ETS, early treatment success (HCV RNA <25 IU/mL at week 4 and target not 
detected at week 8); PR, pegylated interferon alfa-2a and ribavirin. 
 
Fig. 2. Randomization, treatment, and follow-up of study patients 
*Patients who met a stopping rule were classified as having lack of efficacy (virologic 
breakthrough at or after week 4; lack of early virologic response; or lack of virologic 
response at end of treatment). Before week 8, the interactive voice response system 
informed investigators if patients had met criteria to stop treatment due to lack of 
efficacy. After week 8, lack of efficacy was determined by investigators based on 
HCV RNA results. 
 
Fig. 3. Levels of hemoglobin over time 
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Faldaprevir
240 mg QD + PR
Observation Period
Placebo + PR
PR Observation Period
ETS
No ETS
Arm 2
(n=261)
Arm 3
(n=262)
Arm 1
(n=133)
Observation Period
Faldaprevir
120 mg QD + PR
PR Observation Period
ETS
No ETS Faldaprevir
120 mg QD + PR
Placebo + PR
  
656 patients 
randomized
778 patients screened
1 randomized but not treated 1 randomized but not treated
132 treated 259 treated 261 treated
90 completed planned 
48 weeks’ treatment
210 completed planned 24 weeks’ treatment
16 completed 48 weeks’ treatment
207 completed planned 24 weeks’ treatment
15 completed 48 weeks’ treatment
89 completed SVR12 follow-up 249 completed SVR12 follow-up 249 completed SVR12 follow-up
2 randomized but not treated
133 assigned to placebo plus
peginterferon/ribavirin (arm 1)
261 assigned to faldaprevir 120 mg plus
peginterferon/ribavirin (arm 2)
262 assigned to faldaprevir 240 mg plus
peginterferon/ribavirin (arm 3)
22 discontinued treatment before week 24
20 discontinued peginterferon/ribavirin after
week 24
    10 adverse events
    21 lack of efficacy
    9 withdrawals
    1 lost to follow-up
    1 other reason
25 discontinued treatment before week 24
8 discontinued peginterferon/ribavirin after
week 24
    12 adverse events
    15 lack of efficacy
    4 withdrawals
    1 lost to follow-up
    1 protocol violation
34 discontinued treatment before week 24
5 discontinued peginterferon/ribavirin after
week 24
    17 adverse events
    11 lack of efficacy
    5 withdrawals
    3 lost to follow-up
    3 protocol violation
122 patients not entered
98 did not meet inclusion/exclusion criteria
15 withdrew
1 was lost to follow-up
8 were not randomized for another reason
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